Oxford Biomedica said that Sanofi’s decision to terminate collaboration on a haemophilia treatment would have a “negligible” impact on revenue.
Sanofi had given notice to “terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat haemophilia”, Oxford said on Friday.
“The group expects that the impact on revenue will be negligible over the coming 24 month period.”
Santander UK has today made reductions to selected fixed rates across its purchase, remortgage, and buy-to-let range by…
This evening, the US Federal Reserve (Fed) has lowered its benchmark interest rate by 50bps to 4.75-5% target range, wit…
Written by Ranjiv Mann, Senior Fixed Income Portfolio Manager at AllianzGI, ahead of the Bank of England meeting on 19th…
The number of people having to pay tax on their savings will almost double over two years to the end of the current tax…
Written by Shaan Raithatha, senior economist at Vanguard Europe Expect the MPC to keep Bank Rate on hold at 5% at its Se…
After the news last night that the Fed had decided to cut US interest rates for the first time in four years and by more…
Economy, Mortgage and Property
Will they cut, won’t they cut? With mortgage rates going the right way recently, in anticipation of further interest rat…
Mansfield Building Society has signed an agreement with Tata Consultancy Services (TCS) to transform its core banking sy…
Vitality has today announced that leading Asian-inspired food brand itsu will join its Vitality Programme, as an officia…
With the ECB having cut interest rates last week, the Fed expected to cut at their meeting tomorrow, plus the Bank of En…
IFA Talk is our flagship podcast, that fits perfectly into your busy life, bringing the latest insight, analysis, news and interviews to you, wherever you are.
